首页|PD-1抑制剂联合化疗治疗转移性鼻咽癌1例

PD-1抑制剂联合化疗治疗转移性鼻咽癌1例

PD-1 inhibitor combined with chemotherapy in the treatment of metastatic nasopharyngeal carcinoma:a case report

扫码查看
本文回顾性分析了一例晚期鼻咽癌(nasopharyngeal carcinoma,NPC)伴多发肝、肺、淋巴结转移患者的诊治过程.患者接受卡瑞利珠单抗免疫治疗联合化疗后显示出良好的疗效,无进展生存期为55个月.即使治疗期间因新冠疫情中断免疫治疗5个月,患者肿瘤仍得到有效控制,无明显复发转移征象.治疗期间无3~4级治疗相关不良反应,患者生活质量良好.对于复发/转移性NPC,免疫治疗联合化疗给患者带来了显著的生存获益.
This paper retrospectively analyzed the diagnosis and treatment process of a patient with advanced nasopharyngeal carcinoma(NPC)accompanied by multiple liver,lung,and lymph node metastases.The patient underwent camrelizumab immunotherapy in conjunction with chemotherapy,and demonstrated positive efficacy with a progression-free survival of 55 months.Despite a 5-month interruption in immunotherapy treatment caused by the CO VID-19 epidemic,the patient's tumor remained well controlled with no apparent signs of recurrence or metastasis.Throughout the treatment,there were no grade 3-4 treatment-related side effects,and the patient's quality of life remained good.Immunotherapy combined with chemotherapy can bring significant survival benefits to patients with the recurrent/metastatic NPC.

Nasopharyngeal carcinomaPD-1 inhibitorImmunotherapyChemotherapy

程艳双、王娟、金洁莹、吴求吉、钟亚华

展开 >

武汉大学中南医院头颈与儿童肿瘤放化疗科(武汉 430071)

武汉大学中南医院妇科肿瘤放化疗科(武汉 430071)

鼻咽癌 PD-1抑制剂 免疫治疗 化疗

2024

数理医药学杂志
武汉大学,中国工业与应用数学学会,医药数学专业委员会

数理医药学杂志

影响因子:0.479
ISSN:1004-4337
年,卷(期):2024.37(5)
  • 25